<DOC>
	<DOCNO>NCT01358266</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intravitreal injection DE-109 ophthalmic solution .</brief_summary>
	<brief_title>Study Assessing Double-masked Uveitis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Confirmed diagnosis active uveitis 18 year age old Sign inform consent Meet best correct ETDRS visual acuity Uveitis infectious etiology Suspected/confirmed central nervous system ocular lymphoma Primary diagnosis anterior uveitis Uncontrolled glaucoma Use topical oculary medication Implanted device Significant ocular disease Lens/media opacities obscure ocular medium Intraocular surgery treatment Capsulotomy Ocular periocular infection Pupillary dilation History herpetic infection Toxoplasmosis toxoplasmosis scar Ocular malignancy Allergy hypersensitivity study drug Participation uveitis trial within 30 day Monoclonal antibody treatment biologic therapy Any systemic condition/infection Immunosuppressive therapy immunocompromised Malignancy remission Females pregnant lactating female use adequate contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>